Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).
Joseph M. Flynn, DO
Advertisement
Articles by Joseph M. Flynn, DO
Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the impact ibrutinib has had on treating hematologic malignancies.
Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Advertisement
Latest Updated Articles
- Dr. Flynn Discusses Ibrutinib for Hematologic Malignancies
Published: July 28th 2014 | Updated:
Dr. Flynn on Obinutuzumab for the Treatment of CLLPublished: August 25th 2014 | Updated:
Dr. Flynn on CDK Inhibitors for the Treatment of CLLPublished: April 7th 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5